AB0953 PATTERNS OF Bdmards PRESCRIPTION IN SPONDYLOARTHRITIS AFTER FIRST TNFi FAILURE

Scientific Abstracts(2024)

引用 0|浏览0
摘要
Background: Patients with spondyloarthritis (SpA) using tumor necrosis factor inhibitors (TNFi) can have an inadequate response, with discontinuation rates of up to 50-60% in two years [1]. For several years, TNFis were the only biologic disease-modifying anti-rheumatic drugs (bDMARDs) available for SpA and the introduction of IL-17 inhibitors (IL-17i) changed the treatment paradigm [2]. Switching to another mechanism of action (MOA) or cycling to another TNFi after failure of first (1st) TNFi is still a debatable topic. Objectives: To describe clinical characteristics of patients using TNFi in the 1st year of treatment and identify relevant differences between patients who cycled TNFi or switched to MOA after failure of the 1st TNFi. Methods: We conducted a monocentric retrospective study that included patients with SpA according to ASAS classification criteria registered in Reuma.pt (Rheumatic Diseases Portuguese Register). All patients discontinued their 1st TNFi in the 1st year of treatment due to inefficacy and were grouped according to their second (2nd) bDMARD: TNFi cyclers or MOA switchers. Clinical and demographic data were collected. Statistical analysis included chi-square test for categorical variables and non-parametric tests for continuous variables. Results: A total of 44 patients, out of 629, fulfilled the inclusion criteria. Most were female (72,7%) and mean age at diagnosis was 39±11,9 years old. Ankylosing spondylitis was the most common SpA subtype (52,3%), followed by undifferentiated SpA (36,4%) and inflammatory bowel disease associated SpA (11,4%). Peripheral involvement was present in 38,6% patients. Amongst other clinical features, 50% of the patients had enthesitis, 22,7% had psoriasis, two patients had dactylitis and 5 patients had an history of uveitis. Regarding 1st TNFi therapy, adalimumab and golimumab were the choice in 36,4% (n= 16) of the patients, respectively. Etanercept (18,2%, n=8), infliximab (6,8%, n=3) and certolizumab (2,3%, n=1) were other 1st line therapeutic options. After discontinuation of the 1st TNFi, 37 (84,1%) patients cycled to another TNFi and 7 (15,9%) switched MOA. Moreover, 50% (n=22) of the patients started the 2nd bDMARD before 2017, which is relevant giving the timeline of IL-17i approval. Within MOA switchers, all patients were prescribed secukinumab (IL-17i). In this group, there was a tendency for longer treatment duration of 1st TNFi (10,8 (5,7-12,9) vs 8,8 (6,5-12,4) months) and HLA-B27 positivity (42,9% vs 24,3%), but this was not statistically significant. Patients that switched MOA showed a higher prevalence of psoriasis (57,1% vs 16,2%, p=0,037). Additionally, all patients using secukinumab as a 2nd therapeutic option were switched after the year of 2017 (p=0,009, Table 1). When comparing disease activity evaluation between TNFi cyclers and MOA switchers at the time of starting the 1st TNFi and before starting the 2nd bDMARD, there were no relevant differences. MOA switchers had higher prevalence of very high ASDAS activity levels, but this failed to reach statistical significance (p=0,437, Table 2). Conclusion: Patterns of bDMARDs prescription in SpA have been conditioned during several years due to the lack of therapeutic options other than TNFi. Since 2017, novel targets have emerged, and IL-17i have showed efficacy in controlling disease activity. In our study, 50% of the patients started the 2nd line bDMARD before 2017, so, as expected, most patients were TNFi cyclers. The presence of psoriasis was the only clinical factor associated with the decision of MOA switching, and this is in line with current evidence of better skin outcomes with IL-17i [2]. REFERENCES: [1] Bekele, D.I., et al., Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis. Rheumatol Int, 2022. 42(11): p. 1925-1937. [2] Ramiro, S., et al., ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis, 2023. 82(1): p. 19-34. Acknowledgements: NIL. Disclosure of Interests: None declared.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
0
您的评分 :

暂无评分

数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn